Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Mol Cancer Res. 2019 Feb 26;17(6):1351–1364. doi: 10.1158/1541-7786.MCR-18-1068

Figure 5: Pyrimidine biosynthesis metabolites are reduced by combined CPS1 knockdown cells with erlotinib treatment and exogenous pyrimidines can partially rescue cell proliferation.

Figure 5:

HCC4006 cells were treated with erlotinib for vehicle (DMSO) or 100 nM erlotinib for 22 and were processed using UPLC-MS/MS for metabolic profiling as in figure 4 A. Table showing the TOP ten metabolites identified using ANOVA. B. Pathway analysis performed showing the most affected metabolic pathways based on the top 25 significantly changed metabolites. C. Pyrimidine metabolite levels in HCC4006 cell treated with 100 nM erlotinib for 22 hours. D. HCC4006 shNT control or shCPS1 cells treated in triplicate with vehicle (DMSO), 100 nM erlotinib, 1 mM thymidine or thymidine and erlotinib for 6 days. Cell viability was determined by flow cytometry using PI. E. As in D, but with vehicle (DMSO), 100 nM erlotinib, 1 mM uridine or uridine and erlotinib for 6 days. Cell viability was determined by flow cytometry using PI. (ANOVA; *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001).